Adult bone marrow-derived cells for cardiac repair: A systematic review and meta-analysis

Ahmed Abdel-Latif, Roberto Bolli, Imad M. Tleyjeh, Victor Manuel Montori, Emerson C. Perin, Carlton A. Hornung, Ewa K. Zuba-Surma, Mouaz Al-Mallah, Buddhadeb Dawn

Research output: Contribution to journalArticle

778 Citations (Scopus)

Abstract

Background: The results from small clinical studies suggest that therapy with adult bone marrow (BM)-derived cells (BMCs) reduces infarct size and improves left ventricular function and perfusion. However, the effects of BMC transplantation in patients with ischemic heart disease remains unclear. Methods: We searched MEDLINE, EMBASE, Science Citation Index, CINAHL (Cumulative Index to Nursing and Allied Health), and the Cochrane Central Register of Controlled Trials (CENTRAL) (through July 2006) for randomized controlled trials and cohort studies of BMC transplantation to treat ischemic heart disease. We conducted a random-effects meta-analysis across eligible studies measuring the same outcomes. Results: Eighteen studies (N=999 patients) were eligible. The adult BMCs included BM mononuclear cells, BM mesenchymal stem cells, and BM-derived circulating progenitor cells. Compared with controls, BMC transplantation improved left ventricular ejection fraction (pooled difference, 3.66%; 95% confidence interval [CI], 1.93% to 5.40%; P<.001); reduced infarct scar size (?5.49%; 95% CI, ?9.10% to ?1.88%; P=.003); and reduced left ventricular end-systolic volume (?4.80 mL; 95% CI, ?8.20 to ?1.41 mL; P=.006). Conclusions: The available evidence suggests that BMC transplantation is associated with modest improvements in physiologic and anatomic parameters in patients with both acute myocardial infarction and chronic ischemic heart disease, above and beyond conventional therapy. Therapy with BMCs seems safe. These results support conducting large randomized trials to evaluate the impact of BMC therapy vs the standard of care on patient-important outcomes.

Original languageEnglish (US)
Pages (from-to)989-997
Number of pages9
JournalArchives of Internal Medicine
Volume167
Issue number10
DOIs
StatePublished - May 28 2007

Fingerprint

Cell Transplantation
Bone Marrow Cells
Meta-Analysis
Myocardial Ischemia
Confidence Intervals
Stroke Volume
Bone Marrow
Standard of Care
Cell- and Tissue-Based Therapy
Mesenchymal Stromal Cells
Left Ventricular Function
MEDLINE
Cicatrix
Nursing
Cohort Studies
Stem Cells
Therapeutics
Randomized Controlled Trials
Perfusion
Myocardial Infarction

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Adult bone marrow-derived cells for cardiac repair : A systematic review and meta-analysis. / Abdel-Latif, Ahmed; Bolli, Roberto; Tleyjeh, Imad M.; Montori, Victor Manuel; Perin, Emerson C.; Hornung, Carlton A.; Zuba-Surma, Ewa K.; Al-Mallah, Mouaz; Dawn, Buddhadeb.

In: Archives of Internal Medicine, Vol. 167, No. 10, 28.05.2007, p. 989-997.

Research output: Contribution to journalArticle

Abdel-Latif, A, Bolli, R, Tleyjeh, IM, Montori, VM, Perin, EC, Hornung, CA, Zuba-Surma, EK, Al-Mallah, M & Dawn, B 2007, 'Adult bone marrow-derived cells for cardiac repair: A systematic review and meta-analysis', Archives of Internal Medicine, vol. 167, no. 10, pp. 989-997. https://doi.org/10.1001/archinte.167.10.989
Abdel-Latif, Ahmed ; Bolli, Roberto ; Tleyjeh, Imad M. ; Montori, Victor Manuel ; Perin, Emerson C. ; Hornung, Carlton A. ; Zuba-Surma, Ewa K. ; Al-Mallah, Mouaz ; Dawn, Buddhadeb. / Adult bone marrow-derived cells for cardiac repair : A systematic review and meta-analysis. In: Archives of Internal Medicine. 2007 ; Vol. 167, No. 10. pp. 989-997.
@article{7a328d94b78043a2ac09ec10f0f15172,
title = "Adult bone marrow-derived cells for cardiac repair: A systematic review and meta-analysis",
abstract = "Background: The results from small clinical studies suggest that therapy with adult bone marrow (BM)-derived cells (BMCs) reduces infarct size and improves left ventricular function and perfusion. However, the effects of BMC transplantation in patients with ischemic heart disease remains unclear. Methods: We searched MEDLINE, EMBASE, Science Citation Index, CINAHL (Cumulative Index to Nursing and Allied Health), and the Cochrane Central Register of Controlled Trials (CENTRAL) (through July 2006) for randomized controlled trials and cohort studies of BMC transplantation to treat ischemic heart disease. We conducted a random-effects meta-analysis across eligible studies measuring the same outcomes. Results: Eighteen studies (N=999 patients) were eligible. The adult BMCs included BM mononuclear cells, BM mesenchymal stem cells, and BM-derived circulating progenitor cells. Compared with controls, BMC transplantation improved left ventricular ejection fraction (pooled difference, 3.66{\%}; 95{\%} confidence interval [CI], 1.93{\%} to 5.40{\%}; P<.001); reduced infarct scar size (?5.49{\%}; 95{\%} CI, ?9.10{\%} to ?1.88{\%}; P=.003); and reduced left ventricular end-systolic volume (?4.80 mL; 95{\%} CI, ?8.20 to ?1.41 mL; P=.006). Conclusions: The available evidence suggests that BMC transplantation is associated with modest improvements in physiologic and anatomic parameters in patients with both acute myocardial infarction and chronic ischemic heart disease, above and beyond conventional therapy. Therapy with BMCs seems safe. These results support conducting large randomized trials to evaluate the impact of BMC therapy vs the standard of care on patient-important outcomes.",
author = "Ahmed Abdel-Latif and Roberto Bolli and Tleyjeh, {Imad M.} and Montori, {Victor Manuel} and Perin, {Emerson C.} and Hornung, {Carlton A.} and Zuba-Surma, {Ewa K.} and Mouaz Al-Mallah and Buddhadeb Dawn",
year = "2007",
month = "5",
day = "28",
doi = "10.1001/archinte.167.10.989",
language = "English (US)",
volume = "167",
pages = "989--997",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "10",

}

TY - JOUR

T1 - Adult bone marrow-derived cells for cardiac repair

T2 - A systematic review and meta-analysis

AU - Abdel-Latif, Ahmed

AU - Bolli, Roberto

AU - Tleyjeh, Imad M.

AU - Montori, Victor Manuel

AU - Perin, Emerson C.

AU - Hornung, Carlton A.

AU - Zuba-Surma, Ewa K.

AU - Al-Mallah, Mouaz

AU - Dawn, Buddhadeb

PY - 2007/5/28

Y1 - 2007/5/28

N2 - Background: The results from small clinical studies suggest that therapy with adult bone marrow (BM)-derived cells (BMCs) reduces infarct size and improves left ventricular function and perfusion. However, the effects of BMC transplantation in patients with ischemic heart disease remains unclear. Methods: We searched MEDLINE, EMBASE, Science Citation Index, CINAHL (Cumulative Index to Nursing and Allied Health), and the Cochrane Central Register of Controlled Trials (CENTRAL) (through July 2006) for randomized controlled trials and cohort studies of BMC transplantation to treat ischemic heart disease. We conducted a random-effects meta-analysis across eligible studies measuring the same outcomes. Results: Eighteen studies (N=999 patients) were eligible. The adult BMCs included BM mononuclear cells, BM mesenchymal stem cells, and BM-derived circulating progenitor cells. Compared with controls, BMC transplantation improved left ventricular ejection fraction (pooled difference, 3.66%; 95% confidence interval [CI], 1.93% to 5.40%; P<.001); reduced infarct scar size (?5.49%; 95% CI, ?9.10% to ?1.88%; P=.003); and reduced left ventricular end-systolic volume (?4.80 mL; 95% CI, ?8.20 to ?1.41 mL; P=.006). Conclusions: The available evidence suggests that BMC transplantation is associated with modest improvements in physiologic and anatomic parameters in patients with both acute myocardial infarction and chronic ischemic heart disease, above and beyond conventional therapy. Therapy with BMCs seems safe. These results support conducting large randomized trials to evaluate the impact of BMC therapy vs the standard of care on patient-important outcomes.

AB - Background: The results from small clinical studies suggest that therapy with adult bone marrow (BM)-derived cells (BMCs) reduces infarct size and improves left ventricular function and perfusion. However, the effects of BMC transplantation in patients with ischemic heart disease remains unclear. Methods: We searched MEDLINE, EMBASE, Science Citation Index, CINAHL (Cumulative Index to Nursing and Allied Health), and the Cochrane Central Register of Controlled Trials (CENTRAL) (through July 2006) for randomized controlled trials and cohort studies of BMC transplantation to treat ischemic heart disease. We conducted a random-effects meta-analysis across eligible studies measuring the same outcomes. Results: Eighteen studies (N=999 patients) were eligible. The adult BMCs included BM mononuclear cells, BM mesenchymal stem cells, and BM-derived circulating progenitor cells. Compared with controls, BMC transplantation improved left ventricular ejection fraction (pooled difference, 3.66%; 95% confidence interval [CI], 1.93% to 5.40%; P<.001); reduced infarct scar size (?5.49%; 95% CI, ?9.10% to ?1.88%; P=.003); and reduced left ventricular end-systolic volume (?4.80 mL; 95% CI, ?8.20 to ?1.41 mL; P=.006). Conclusions: The available evidence suggests that BMC transplantation is associated with modest improvements in physiologic and anatomic parameters in patients with both acute myocardial infarction and chronic ischemic heart disease, above and beyond conventional therapy. Therapy with BMCs seems safe. These results support conducting large randomized trials to evaluate the impact of BMC therapy vs the standard of care on patient-important outcomes.

UR - http://www.scopus.com/inward/record.url?scp=33947305414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947305414&partnerID=8YFLogxK

U2 - 10.1001/archinte.167.10.989

DO - 10.1001/archinte.167.10.989

M3 - Article

C2 - 17533201

AN - SCOPUS:33947305414

VL - 167

SP - 989

EP - 997

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 10

ER -